Which has stronger valuation & earnings, CBLL or WRBY?

Warby Parker has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $95.07M 7.87 -$53.41M -$1.63 N/A Warby Parker $871.91M 3.36 $1.64M $0.02 1,366.75

Is CBLL or WRBY more profitable?

Warby Parker has a net margin of 0.15% compared to CeriBell's net margin of -63.51%. Warby Parker's return on equity of 2.30% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Warby Parker 0.15% 2.30% 1.18%

Which has preferable valuation and earnings, CBLL or TMDX?

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $95.07M 7.87 -$53.41M -$1.63 N/A TransMedics Group $605.49M 4.44 $190.29M $4.40 17.67

Which has higher earnings and valuation, AXGN or CBLL?

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $238.11M 9.94 -$15.70M -$0.64 N/A CeriBell $95.07M 7.87 -$53.41M -$1.63 N/A

Is AXGN or CBLL more profitable?

AxoGen has a net margin of -13.21% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -9.63% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% CeriBell -63.51% -38.19% -30.92%

Which has better valuation and earnings, LMAT or CBLL?

LeMaitre Vascular has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 8.60 $57.73M $2.71 34.66 CeriBell $95.07M 7.87 -$53.41M -$1.63 N/A

CeriBell (CBLL) Competitors

$19.73 +1.12 (+6.02%)

Closing price 06/25/2026 04:00 PM Eastern

Extended Trading

$19.73 0.00 (0.00%)

As of 06/25/2026 04:12 PM Eastern

Compare

CBLL vs. WRBY, TMDX, ESTA, AXGN, and LMAT

Should you buy CeriBell stock or one of its competitors? MarketBeat compares CeriBell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CeriBell include Warby Parker (WRBY), TransMedics Group (TMDX), Establishment Labs (ESTA), AxoGen (AXGN), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.

How does CeriBell compare to Warby Parker?

CeriBell (NASDAQ:CBLL) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Warby Parker has a net margin of 0.15% compared to CeriBell's net margin of -63.51%. Warby Parker's return on equity of 2.30% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Warby Parker	0.15%	2.30%	1.18%

CeriBell presently has a consensus price target of $22.20, suggesting a potential upside of 12.52%. Warby Parker has a consensus price target of $29.50, suggesting a potential upside of 7.92%. Given CeriBell's stronger consensus rating and higher probable upside, research analysts plainly believe CeriBell is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

CeriBell has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Warby Parker has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market.

Warby Parker has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$95.07M	7.87	-$53.41M	-$1.63	N/A
Warby Parker	$871.91M	3.36	$1.64M	$0.02	1,366.75

In the previous week, Warby Parker had 5 more articles in the media than CeriBell. MarketBeat recorded 6 mentions for Warby Parker and 1 mentions for CeriBell. CeriBell's average media sentiment score of 1.89 beat Warby Parker's score of 1.03 indicating that CeriBell is being referred to more favorably in the media.

Company	Overall Sentiment
CeriBell	Very Positive
Warby Parker	Positive

93.2% of Warby Parker shares are held by institutional investors. 20.1% of CeriBell shares are held by insiders. Comparatively, 16.8% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Warby Parker beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does CeriBell compare to TransMedics Group?

CeriBell (NASDAQ:CBLL) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

CeriBell has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

In the previous week, TransMedics Group had 2 more articles in the media than CeriBell. MarketBeat recorded 3 mentions for TransMedics Group and 1 mentions for CeriBell. CeriBell's average media sentiment score of 1.89 beat TransMedics Group's score of 1.22 indicating that CeriBell is being referred to more favorably in the media.

Company	Overall Sentiment
CeriBell	Very Positive
TransMedics Group	Positive

99.7% of TransMedics Group shares are held by institutional investors. 20.1% of CeriBell shares are held by insiders. Comparatively, 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TransMedics Group has a net margin of 27.04% compared to CeriBell's net margin of -63.51%. TransMedics Group's return on equity of 22.38% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
TransMedics Group	27.04%	22.38%	8.46%

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 12.52%. TransMedics Group has a consensus target price of $134.50, indicating a potential upside of 72.99%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$95.07M	7.87	-$53.41M	-$1.63	N/A
TransMedics Group	$605.49M	4.44	$190.29M	$4.40	17.67

Summary

TransMedics Group beats CeriBell on 12 of the 17 factors compared between the two stocks.

How does CeriBell compare to Establishment Labs?

CeriBell (NASDAQ:CBLL) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

CeriBell has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Establishment Labs had 2 more articles in the media than CeriBell. MarketBeat recorded 3 mentions for Establishment Labs and 1 mentions for CeriBell. CeriBell's average media sentiment score of 1.89 beat Establishment Labs' score of 0.88 indicating that CeriBell is being referred to more favorably in the media.

Company	Overall Sentiment
CeriBell	Very Positive
Establishment Labs	Positive

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 12.52%. Establishment Labs has a consensus target price of $87.14, indicating a potential downside of 2.16%. Given CeriBell's stronger consensus rating and higher possible upside, equities analysts clearly believe CeriBell is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Establishment Labs has a net margin of -19.05% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Establishment Labs	-19.05%	-218.77%	-12.31%

72.9% of Establishment Labs shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Establishment Labs has higher revenue and earnings than CeriBell. Establishment Labs is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$95.07M	7.87	-$53.41M	-$1.63	N/A
Establishment Labs	$211.08M	12.42	-$51.06M	-$1.49	N/A

Summary

Establishment Labs beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does CeriBell compare to AxoGen?

AxoGen (NASDAQ:AXGN) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AxoGen has a net margin of -13.21% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -9.63% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
CeriBell	-63.51%	-38.19%	-30.92%

AxoGen presently has a consensus target price of $46.50, indicating a potential upside of 4.52%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 12.52%. Given CeriBell's stronger consensus rating and higher probable upside, analysts clearly believe CeriBell is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, AxoGen had 1 more articles in the media than CeriBell. MarketBeat recorded 2 mentions for AxoGen and 1 mentions for CeriBell. CeriBell's average media sentiment score of 1.89 beat AxoGen's score of 1.08 indicating that CeriBell is being referred to more favorably in the news media.

Company	Overall Sentiment
AxoGen	Positive
CeriBell	Very Positive

AxoGen has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	9.94	-$15.70M	-$0.64	N/A
CeriBell	$95.07M	7.87	-$53.41M	-$1.63	N/A

Summary

AxoGen beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does CeriBell compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, LeMaitre Vascular had 4 more articles in the media than CeriBell. MarketBeat recorded 5 mentions for LeMaitre Vascular and 1 mentions for CeriBell. CeriBell's average media sentiment score of 1.89 beat LeMaitre Vascular's score of 0.94 indicating that CeriBell is being referred to more favorably in the news media.

Company	Overall Sentiment
LeMaitre Vascular	Positive
CeriBell	Very Positive

LeMaitre Vascular has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.60	$57.73M	$2.71	34.66
CeriBell	$95.07M	7.87	-$53.41M	-$1.63	N/A

LeMaitre Vascular has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

LeMaitre Vascular presently has a consensus target price of $112.60, suggesting a potential upside of 19.88%. CeriBell has a consensus target price of $22.20, suggesting a potential upside of 12.52%. Given LeMaitre Vascular's higher possible upside, equities research analysts plainly believe LeMaitre Vascular is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

LeMaitre Vascular has a net margin of 24.35% compared to CeriBell's net margin of -63.51%. LeMaitre Vascular's return on equity of 15.36% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
CeriBell	-63.51%	-38.19%	-30.92%

84.6% of LeMaitre Vascular shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 20.1% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

LeMaitre Vascular beats CeriBell on 11 of the 15 factors compared between the two stocks.

Get CeriBell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBLL vs. The Competition

Export

Metric	CeriBell	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$706.12M	$8.41B	$6.61B	$12.27B
Dividend Yield	N/A	2.54%	2.67%	5.89%
P/E Ratio	-12.10	15.71	25.77	23.97
Price / Sales	7.87	6.37	544.12	99.70
Price / Cash	N/A	17.16	46.33	53.91
Price / Book	4.71	3.27	10.53	6.32
Net Income	-$53.41M	$226.25M	$3.57B	$337.22M
7 Day Performance	9.43%	-0.65%	0.77%	-1.24%
1 Month Performance	4.95%	-2.96%	0.19%	-0.63%
1 Year Performance	2.28%	0.62%	30.81%	27.95%

CeriBell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBLL CeriBell	1.3988 of 5 stars	$19.73 +6.0%	$22.20 +12.5%	+2.1%	$706.12M	$95.07M	N/A	N/A	Positive News
WRBY Warby Parker	3.2668 of 5 stars	$25.85 -4.2%	$29.50 +14.1%	+25.6%	$2.77B	$871.91M	1,293.15	4,036	Positive News
TMDX TransMedics Group	4.4498 of 5 stars	$74.02 -2.0%	$134.50 +81.7%	-39.5%	$2.56B	$605.49M	16.82	210	Positive News
ESTA Establishment Labs	1.4899 of 5 stars	$86.06 flat	$87.14 +1.3%	+137.5%	$2.53B	$211.08M	N/A	1,004	Gap Up
AXGN AxoGen	2.3151 of 5 stars	$45.09 +0.3%	$46.50 +3.1%	+334.0%	$2.40B	$238.11M	N/A	450	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBLL) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CeriBell (CBLL) Competitors

CBLL vs. WRBY, TMDX, ESTA, AXGN, and LMAT

How does CeriBell compare to Warby Parker?

Summary

How does CeriBell compare to TransMedics Group?

Summary

How does CeriBell compare to Establishment Labs?

Summary

How does CeriBell compare to AxoGen?

Summary

How does CeriBell compare to LeMaitre Vascular?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CeriBell (CBLL) Competitors

CBLL vs. WRBY, TMDX, ESTA, AXGN, and LMAT

How does CeriBell compare to Warby Parker?

Is CBLL or WRBY more profitable?

Do analysts rate CBLL or WRBY?

Which has more volatility & risk, CBLL or WRBY?

Which has stronger valuation & earnings, CBLL or WRBY?

Does the media prefer CBLL or WRBY?

Do institutionals & insiders hold more shares of CBLL or WRBY?

Summary

How does CeriBell compare to TransMedics Group?

Which has more volatility & risk, CBLL or TMDX?

Does the media favor CBLL or TMDX?

Do institutionals and insiders have more ownership in CBLL or TMDX?

Is CBLL or TMDX more profitable?

Do analysts prefer CBLL or TMDX?

Which has preferable valuation and earnings, CBLL or TMDX?

Summary

How does CeriBell compare to Establishment Labs?

Which has more volatility & risk, CBLL or ESTA?

Does the media prefer CBLL or ESTA?

Do analysts recommend CBLL or ESTA?

Is CBLL or ESTA more profitable?

Do institutionals & insiders have more ownership in CBLL or ESTA?

Which has preferable earnings and valuation, CBLL or ESTA?

Summary

How does CeriBell compare to AxoGen?

Do insiders and institutionals have more ownership in AXGN or CBLL?

Is AXGN or CBLL more profitable?

Do analysts rate AXGN or CBLL?

Does the media favor AXGN or CBLL?

Which has more volatility & risk, AXGN or CBLL?

Which has higher earnings and valuation, AXGN or CBLL?

Summary

How does CeriBell compare to LeMaitre Vascular?

Does the media refer more to LMAT or CBLL?

Which has better valuation and earnings, LMAT or CBLL?

Which has more volatility & risk, LMAT or CBLL?

Do analysts rate LMAT or CBLL?

Is LMAT or CBLL more profitable?

Do insiders and institutionals believe in LMAT or CBLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools